6,335 trials (keyword fallback)
Carcinoma, Basal Cell · Carcinoma, Squamous Cell · Skin Neoplasms
Primary: The Time to Diagnosis of the First Keratinocyte Carcinoma (KC) on the Face or Ears for Which Surgery is Performed — 3.37; 3.52 years — p=0.93
Kangaroo Care · Video · Prenatal Education
Primary: Intention to Practice Skin-to-skin Contact After Birth — 100; 107; NA; 118 Participants
Squamous Cell Carcinoma of Skin · Carcinoma, Squamous Cell
Primary: Objective Response Rate (ORR) — 4; 1; 1 Participants
Head and Neck Neoplasms · Pheochromocytoma · Colorectal Neoplasms
Primary: Response Rate — 0; 0; 26; 11 Participants
Mouth Neoplasms · Head and Neck Neoplasms · Tongue Neoplasms
Primary: Percent (%) Change in Levels of pS6, pAKt473, and Ki-67 — -60.60; -67.24; -31.48; 100.00 percentage of change from baseline
Dermatitis, Atopic
Primary: Skin Barrier Strengthening Effect by Measurement of Trans Epidermal Water Loss (TEWL) Before and After Induction of Skin Irritation — 19.790; 24.680; 29.648; 28.646 TEWL…
Non-small Cell Lung Cancer
Primary: Part 1: Overall Survival (OS) — 15.9; 20.1; 13.9 months — p=0.1782
Pre-cancerous Geriatric Skin
Primary: Difference in Basal Layer Keratinocytes Positive for Both Ki67 and Thymine Dimers — 21.5; 14.7 positive cells/1000 basal layer cells
Basal Cell Carcinoma · Squamous Cell Carcinoma in Situ
Primary: Tumor Clearance — 2; 2; 5 Participants
Non Small Cell Lung Cancer
Primary: 3-Year Overall Survival Rate — 45 percentage of participants
Multiple Sclerosis
Primary: Number of Patients With a Return of Disease Activity After the Third Month Post-first-infusion — 3; 6 Participants
Non-Squamous Non-Small Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer
Primary: Overall Survival (OS) in the TC3 or IC3-WT Populations — 13.1; 20.2 Months — p=0.0106
Solid Tumors
Primary: Dose Escalation Cohort (Excluding Once Weekly Avelumab 10 mg/kg Cohort): Number of Participants Experiencing Dose Limiting Toxicities (DLTs) — 0; 0; 0; 1 Participants
Arthroplasty, Replacement, Hip
Primary: Identification of the Random Initials by the Reviewing Orthopaedic Surgeons — 209; 296 number of correctly identified initals
Metastatic Squamous Cell Carcinoma of the Hypopharynx · Metastatic Squamous Cell Carcinoma of the Larynx · Metastatic Squamous Cell Carcinoma of the Oral Cavity
Primary: Progression Free Survival (PFS) — 6.08; 4.4 months